-
Ixazomib (trade name Ninlaro) is a drug for the
treatment of
multiple myeloma, a type of
white blood cell cancer, in
combination with
other drugs. It is...
- ciclesonide. On November, the U.S. Food and Drug
Administration approved Ixazomib developed by
Takeda for use in
combination with
lenalidomide and dexamethasone...
- performance-linked cost
reduction for
multiple myeloma, and this was accepted.
Ixazomib, a
proteasome inhibitor that is
given by
mouth Peter Elliott (pharmacologist)...
- pomalidomide), and a
proteasome inhibitor (e.g., or bortezomib,
carfilzomib or
ixazomib), in
combination with a
steroid (e.g., dexamethasone).
While triplet therapies...
-
Palbociclib Ribociclib Seliciclib†) PrI
Bortezomib Carfilzomib Oprozomib Ixazomib PhI (Anagrelide)
IMPDI (Tiazofurin§) LI (Masoprocol) PARP
inhibitor (Fuzuloparib)...
-
Palbociclib Ribociclib Seliciclib†) PrI
Bortezomib Carfilzomib Oprozomib Ixazomib PhI (Anagrelide)
IMPDI (Tiazofurin§) LI (Masoprocol) PARP
inhibitor (Fuzuloparib)...
-
Palbociclib Ribociclib Seliciclib†) PrI
Bortezomib Carfilzomib Oprozomib Ixazomib PhI (Anagrelide)
IMPDI (Tiazofurin§) LI (Masoprocol) PARP
inhibitor (Fuzuloparib)...
-
Palbociclib Ribociclib Seliciclib†) PrI
Bortezomib Carfilzomib Oprozomib Ixazomib PhI (Anagrelide)
IMPDI (Tiazofurin§) LI (Masoprocol) PARP
inhibitor (Fuzuloparib)...
-
Palbociclib Ribociclib Seliciclib†) PrI
Bortezomib Carfilzomib Oprozomib Ixazomib PhI (Anagrelide)
IMPDI (Tiazofurin§) LI (Masoprocol) PARP
inhibitor (Fuzuloparib)...
-
Palbociclib Ribociclib Seliciclib†) PrI
Bortezomib Carfilzomib Oprozomib Ixazomib PhI (Anagrelide)
IMPDI (Tiazofurin§) LI (Masoprocol) PARP
inhibitor (Fuzuloparib)...
